CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Lonsurf for Metastatic Colorectal Cancer – Details

Project Number PC0122-000
Brand Name Lonsurf
Generic Name Trifluridine and Tipiracil
Strength 15 mg & 20 mg
Tumour Type Gastrointestinal
Indication Metastatic Colorectal Cancer
Funding Request For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents
Review Status Complete
Pre Noc Submission Yes
NOC Date January 25, 2018
Manufacturer Taiho Pharma Canada, Inc.
Sponsor Taiho Pharma Canada, Inc.
Submission Date November 6, 2017
Submission Deemed Complete November 13, 2017
Submission Type Initial
Prioritization Requested Requested and Granted
Stakeholder Input Deadline ‡ November 20, 2017
Check-point meeting January 9, 2018
pERC Meeting April 19, 2018
Initial Recommendation Issued May 3, 2018
Feedback Deadline ‡ May 17, 2018
pERC Reconsideration Meeting June 21, 2018
Final Recommendation Issued July 6, 2018
Notification to Implement Issued July 23, 2018
Therapeutic Area Metastatic Colorectal Cancer
Recommendation Type Do not reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.